Regeneron Pharmaceuticals, Inc. (REGN) - Stock Analysis

Regeneron Pharmaceuticals, Inc. Financial Analysis

Current Price: $618.95 +2.66%

Market Cap: $63.77B

Sector: Healthcare

P/E Ratio: 17.92

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vei

Report Contents

  • Income Statement Analysis (5-year history)
  • Balance Sheet Overview
  • Cash Flow Statement
  • Key Financial Ratios
  • Valuation Metrics (P/E, EV/EBITDA, P/S)
  • Peer Comparison
  • Revenue & Earnings Growth Trends
  • Margin Analysis
  • Analyst Price Targets
  • DCF Valuation Model